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Pregnancies are rare in women with pituitary adenomas, which may relate to hormone 
excess from secretory subtypes such as prolactinomas or corticotroph adenomas.  
Decreased fertility may also result from pituitary hormone deficiencies due to compression 
of the gland by large tumours and/or surgical or radiation treatment of the lesion. 
Counselling premenopausal women with pituitary adenomas about their chance of 
conceiving spontaneously or with assisted reproductive technology, and the optimal pre-
conception treatment, should start at the time of initial diagnosis. The normal physiological 
changes during pregnancy need to be considered when interpreting endocrine tests in 
women with pituitary adenomas. Dose adjustments in hormone substitution therapies may 
be needed across the trimesters. When medical therapy is used for pituitary hormone 
excess, consideration should be given to the known efficacy and safety data specific to 
pregnant women for each therapeutic option. In healthy women, pituitary gland size 
increases during pregnancy. Since some pituitary adenomas also enlarge during pregnancy, 
there is a risk of visual impairment, especially in women with macroadenomas or tumours 
near the optic chiasm. Pituitary apoplexy represents a rare acute complication of adenomas 
requiring surveillance, with surgical intervention needed in some cases. This guideline 
describes the choice and timing of diagnostic tests and treatments from the preconception 
stage until after delivery, taking into account adenoma size, location and endocrine activity. 
In most cases, pregnant women with pituitary adenomas should be managed by a 




1. Overview of recommendations  
 
General recommendations: Preconception stage 
 
R.1.1. We recommend that women of reproductive age with a diagnosis of a pituitary 
adenoma be counselled about their potential fertility and pregnancy outcomes as early as 
possible.  
R.1.2. We recommend that women of reproductive age with a diagnosis of pituitary 
adenoma, functioning or non-functioning, who consider pregnancy, be managed by an 
endocrinologist. 
R.1.3. We recommend that management of women of reproductive age with a large 
pituitary adenoma (>1cm), Cushing’s disease or acromegaly, who consider pregnancy, be 
discussed in a multidisciplinary team.  
R.1.4. We recommend that in women with a diagnosis of pituitary adenoma and 
hypopituitarism, hormone replacement therapy should be initiated or optimized prior to 
becoming pregnant. 
 
General recommendations: pregnancy 
 
R.2.1. We recommend that pregnant women with a known pituitary adenoma, in particular 
those with a large pituitary adenoma (>1cm), Cushing’s disease or acromegaly, and those 
with pituitary deficiencies, should be followed by an endocrinologist and an advanced nurse 
practitioner where relevant. The frequency depends on the underlying condition and 
individualised needs. 
R.2.2. We recommend that pregnant women with diagnosed hypopituitarism should have 
regular clinical and hormonal follow-up by an endocrinologist and an advanced nurse 
practitioner where relevant.  
R.2.3. We recommend that women and their partners be provided with education for 
glucocorticoid stress dose adjustment and measures on how to prevent or manage adrenal 
crisis during pregnancy.  
R.2.4. We recommend performing an MRI without contrast in pregnancy in case of 




R.2.5. We recommend that neuro-ophthalmologic examination in pregnancy be performed 
for adenomas impinging visual pathways or in case of suspected tumour progression or 
pituitary apoplexy.  
R.2.6. We recommend considering surgery in pregnant women with deterioration of vision, 
ophthalmoplegia or severe headache attributable to tumour enlargement if medical tumour 
treatment is unfeasible or ineffective ().  
R.2.7. If surgery is indicated, we suggest to perform transsphenoidal surgery in the second 
trimester if the clinical course allows this (). 
R.2.8. We recommend not to perform radiotherapy during pregnancy. 
 
General recommendations: Delivery and breastfeeding 
 
R.3.1. We suggest that pregnant women with pituitary adenomas should receive standard 
obstetrical care but recommend close maternal and fetal surveillance. 
R.3.2. In general, breastfeeding is feasible and not contra-indicated.  
 
Nonfunctioning adenomas (NFAs) 
 
R.4.1. In women with a NFA near the optic chiasm who are planning a pregnancy, surgery 
may be considered to reduce the risk of chiasmal compression and to enhance fertility. 
R.4.2. We suggest that for women with intrasellar nonfunctioning microadenomas and an 
uneventful pregnancy, there is no need for routine endocrinological follow-up during 
pregnancy. 
R.4.3. We recommend that for macroadenomas and/or extrasellar NFAs, neuro-
ophthalmologic and, if indicated, MRI examination should be performed only in case of 
symptoms of tumour progression or pituitary apoplexy during pregnancy. 
R.4.4. We recommend that in case of a clinical need to reduce adenoma volume during 
pregnancy, surgery is the preferred option (). 
R.4.5. We recommend awaiting re-assessment of pituitary imaging and function until after 







R.5.1. We recommend treating women with a prolactinoma, who are actively seeking 
pregnancy, with a dopamine agonist and strive for normalisation of prolactin concentrations 
and restoration of regular ovulatory cycles (). 
R.5.2. We recommend medical treatment as first choice therapy for women with a 
prolactinoma and actively seeking pregnancy; transsphenoidal surgery can be considered in 
individual cases (). 
R.5.3. We recommend cabergoline as medical treatment at the lowest possible effective 
dose until pregnancy is confirmed (). 
R.5.4. We recommend stopping the dopamine agonist once pregnancy is established. 
However, dopamine agonists may be given for a longer gestational period in specific 
circumstances (). 
R.5.5. We recommend not measuring prolactin during pregnancy. 
R.5.6. We suggest that for women with a small intrasellar microprolactinoma, and normal 
pituitary function pre-pregnancy, there is no need for routine endocrinological follow-up 
during pregnancy. 
R.5.7. We suggest careful and regular monitoring for tumour growth in pregnant women 
with a large macroprolactinoma or a prolactinoma close to the optic chiasm ().  
R.5.8. We recommend to consider restarting dopamine agonists in pregnancy in case of 
symptoms of progressive prolactinoma growth. Surgery should be used only in case of 
medical failure or symptomatic apoplexy (). 
R.5.9. For women with a prolactinoma, breastfeeding is usually feasible and not contra-
indicated, but we recommend to take into account individual circumstances like tumour size 
and symptoms. 
R.5.10. We recommend reassessing prolactinoma status after every pregnancy before 
considering restarting therapy. 
 
Acromegaly 
R.6.1. In women with acromegaly considering pregnancy, we recommend assessment of 




R.6.2. In women with newly diagnosed acromegaly seeking pregnancy, surgery is 
recommended as first line therapy. 
R.6.3. In women with mild acromegaly, no comorbid conditions and regular ovulatory cycles, 
pregnancy is considered safe and medical or surgical treatment can be postponed until after 
delivery. 
R.6.4. We suggest that for women with acromegaly seeking pregnancy and who have an 
indication for medical treatment, somatostatin analogues or cabergoline can be used until 
confirmation of pregnancy if surgery is not an option. Pegvisomant should be reserved for 
selected uncontrolled cases (). 
R.6.5. We recommend to consider stopping drugs for acromegaly once pregnancy is 
established ().  
R.6.6. We recommend not to measure GH and IGF-I during pregnancy. 
R.6.7. We suggest that for pregnant women with large adenomas, or adenomas close to the 
optic chiasm, regular neuro-ophthalmologic and, if necessary, pituitary MRI examination be 
performed. 
R.6.8. We suggest to consider starting or restarting medical treatment for tumour control 
and severe clinical symptoms attributable to acromegaly ().  
R.6.9. In acromegaly, breastfeeding is feasible and not contra-indicated, but we recommend 
to take individual circumstances like drug use and disease activity into account. 




R.7.1. We recommend that women with active Cushing’s syndrome be advised not to get 
pregnant.  
R.7.2. Evaluation of hypercortisolism during pregnancy is difficult; we suggest to consider 
testing only for high clinical suspicion of new diagnosis of Cushing’s disease. 
R.7.3. We recommend that in women with Cushing’s disease, medically treated and 
considering pregnancy, pros and cons of different therapeutic options to reduce cortisol 
should be carefully considered (). 
R.7.4. We recommend that pregnant women with active or medically treated Cushing’s 




R.7.5. We suggest to consider treating pregnant women with active Cushing’s disease with 
prophylactic anticoagulation (low molecular weight heparin [LMWH]). 
R.7.6. We recommend to re-assess disease activity after pregnancy.  
R.7.7. We recommend that breastfeeding be considered.  
 
 
2. Introduction: The pituitary gland and endocrine milieu in 
pregnancy 
 
Pregnancy changes the morphology and function of the pituitary gland. The gland size 
increases and reaches its maximal volume in late pregnancy and the first days postpartum 
with a height of up to 12 mm followed by a gradual decline to normal size within 6 months 
after delivery (1-3). This growth is related to lactotroph hyperplasia starting in the first 
month of pregnancy and due to the increased concentrations of oestradiol (Ε2) (4).  
The placenta is a hormone-producing organ that interacts with the pituitary gland. Starting 
in the first weeks of pregnancy, the placenta produces oestrogens and progesterone, which 
increase exponentially until delivery, whereas ovarian production subsides (5-7). When 
interpreting hormone concentrations in pregnancy, increased production of binding 
proteins due to increased oestradiol concentrations has to be considered. In parallel, due to 
the stimulatory effect of oestradiol, there is an increased prolactin (PRL) production with 
serum concentrations reaching approximately 6 and 10-fold the upper limit of the reference 
range of non-pregnant women in the second and third trimester, respectively (7, 8). Human 
placental lactogen (hPL), which is structurally related to PRL and growth hormone (GH), is 
released into the maternal circulation from the first weeks of gestation until delivery (5, 6).  
From gestational week 5, the placenta produces increasing amounts of GH (hPGH) resulting 
in suppression of circulating pituitary GH to undetectable levels after gestational week 24 (5, 
8). Serum insulin-like growth factor-I (IGF-I) levels increase significantly above the age-
specific reference range for non-pregnant women (5, 9).  
Human chorionic gonadotrophin (hCG) is detectable in the maternal circulation after 
embryo implantation, peaks around week 10 and thereafter declines until week 20 to lower 




pattern of TSH and hCG is present in the first trimester (10, 12). Due to increased 
concentrations of thyroxine binding globulin (TBG), circulating levels of total thyroxine (T4) 
and triiodothyronine (T3) are elevated (10, 11) in pregnancy, and interpretation of thyroid 
function tests therefore requires appropriate reference ranges (11, 13). Free T4 levels 
decline during pregnancy to levels in the low reference range for non-pregnancy.  
Pregnancy is associated with activation of the maternal hypothalamic-pituitary-adrenal 
(HPA) axis that leads to increased levels of circulating adrenocorticotropic hormone (ACTH) 
and cortisol (both free and total) as well as 24h-urinary free cortisol excretion. The placenta 
produces large amounts of corticotropin releasing hormone (CRH) and its related urocortin 
peptides (14, 15), the circulating concentrations of which rise exponentially in the third 
trimester of pregnancy (16, 17). The placenta has also 11β-hydroxysteroid dehydrogenase 
type 2 activity converting cortisol to cortisone. Although the concentration of plasma 
cortisol is elevated during pregnancy, the diurnal pattern is preserved (8, 18).  
Increased placental vasopressinase activity is counterbalanced by increased pituitary 
vasopressin release in normal pregnancy but may manifest as transient diabetes insipidus or 




3.1. Guideline working group  
These guidelines were developed on behalf of The European Society of Endocrinology (ESE), 
the chairs of the working group Anton Luger and Olaf Dekkers being appointed by the ESE 
Clinical Committee. Olaf Dekkers served as methodological expert, Beverly MK Biller as 
representative of the Endocrine Society, USA, Rasa Verkauskiene as European Society for 
Paediatric Endocrinology (ESPE) representative, Sofia Llahana as ESE Nurses Representative, 
Nienke Biermasz as European Neuroendocrine Association (ENEA) representative, Susan 
Webb as European Reference Network on Rare Endocrine Conditions (ENDO-ERN) 
representative, Fahrettin Kelestimur as Pituitary Society representative and Gesthimani 
Mintziori as European Young Endocrinologists and Scientists (EYES) representative. The 
other members were suggested by the chairs and approved by the Clinical Committee of 




Luger (Austria), Olaf Dekkers (the Netherlands), Jens Otto Jorgensen (Denmark), Philippe 
Chanson (France), Dominique Maiter (Belgium), Fahrettin Kelestimur (Turkey), Beverly MK 
Biller (USA), Susan Webb (Spain), Nienke Biermasz (the Netherlands), and Gesthimani 
Mintziori (Greece), an endocrine nurse Sofia Llahana (UK), an obstetrician and gynaecologist 
Felice Petraglia (Italy), a neurosurgeon Michael Buchfelder (Germany), and a paediatric 
endocrinologist Rasa Verkauskiene (Lithuania). Leonie Broersen joined the guideline working 
group for methodology support. The working group had two in-person meetings (February 
2019 and November 2019) and communicated by phone and email. Consensus was reached 
upon discussion; minority positions were taken into account in the rationale behind 
recommendations. Prior to the process, all participants completed conflict of interest forms. 
 
3.2. Target group  
This guideline was developed for health care providers who may see pregnant patients with 
pituitary adenomas. In general, these women (with the exception of those with small 
nonfunctioning adenomas and microprolactinomas) should preferably be managed by a 
multidisciplinary team in expert pituitary centers, including Pituitary Tumor Centers of 
Excellence (PTCOE) (20) / Endo-ERN Reference Centers and their affiliated regional 
healthcare providers. General practitioners and patients might also find the guideline useful. 
The guideline can serve as a source document for the preparation of patient information 
leaflets and educational materials. 
 
3.3. Aims  
The purpose of this guideline is to provide clinicians with practical guidance for the 
management of patients with a pituitary adenoma during pregnancy or considering 
pregnancy. In clinical practice, both the recommendations and the clinical judgment of the 
treating physician should be taken into account. Recommendations are not meant to 
replace clinical acumen. Certain recommendations may not be feasible in individual 





3.4. Summary of methods used for guideline development 
The methods used for establishing such guidelines have been described in detail previously 
(21). In short, the guideline used GRADE (Grading of Recommendations, Assessment, 
Development, and Evaluation) as a methodological basis. The first step was to define clinical 
questions (see Section 3.5); the second step was a systematic literature search (see Section 
3.6). After including all relevant articles for each clinical question, we rated the quality of the 
evidence, and estimated an average effect for specific outcomes where possible. The quality 
of the evidence behind the recommendations was classified as very low (), low 
(), moderate (), or strong (). Not all recommendations were formally 
graded (see below).  
 
For the recommendations, we considered the quality of the evidence, the balance of 
desirable and undesirable outcomes, and individual values and preferences (patient 
preferences, goals for health, costs, management inconvenience, feasibility of 
implementation, etc.) (22, 23). The recommendations are worded as “recommend” (strong 
recommendation) or “suggest” (weak recommendation). The meaning of a strong 
recommendation is that all reasonably informed persons (clinicians, politicians, and 
patients) would want the management in accordance with the recommendation. For a weak 
recommendation, most persons would still act in accordance with the guideline, but a 
substantial number would not (23).  
 
Formal evidence syntheses were performed and graded only for recommendations 
addressing our initial clinical questions (see Section 3.5). Other recommendations were 
based on good practice, experience of the panelists and were not formally graded (24). All 
recommendations are accompanied by an explanation. 
 
3.5. Clinical questions, eligibility criteria and endpoint definition 
At the start of this guideline process, the committee members formulated 21 clinical 
questions regarding diagnosis, treatment, and outcome related to pregnant women with a 
pituitary adenoma. Out of these 21 clinical questions, the five most relevant questions were 




Discrepancies in results and estimations of our findings compared with previously published 
reviews (25, 26) are mainly due to strict application of inclusion criteria, e.g. not including 
review articles, which also minimizes risk of bias by including the same population multiple 
times. 
 
3.6. Description of search and selection of literature (Table 1 and Figure 1) 
We searched four electronic medical databases (PubMed, Embase, Web of Science, and 
COCHRANE). The literature search for questions I-III was performed in July 2019, and the 
literature search for questions IV-V was performed in September 2019. Additionally, all 
searches were repeated in PubMed in November 2019, references of included articles were 
checked to identify potentially relevant additional articles.  
 
For question I (safety profile of medical treatment of prolactinomas in pregnancy), we 
identified 1235 papers, 46 were included, 3 were added after searching through the 
references, and 2 were added in November 2019, for a total of 51 studies. For sub-questions 
Ia (safety profile of medical treatment of hyperprolactinaemia in pregnancy) and Ib (safety 
profile of medical treatment from studies combining data of prolactinoma and 
hyperprolactinaemia in pregnancy), 26 additional studies were included. For question II 
(safety profile of medical treatment of acromegaly in pregnancy), we identified 381 papers, 
47 were included. For question III (safety profile of medical treatment of Cushing’s disease 
(CD) in pregnancy), we identified 248 papers, 10 met the inclusion criteria. For question IV 
(incidence of tumour growth in pregnancy), we included 4 studies on acromegaly, 18 studies 
on prolactinomas and one on non-functioning pituitary adenomas; no studies on CD could 
be included. For question V (safety of pituitary surgery), we included 28 papers. A flow 
diagram of study inclusion is presented in Figure 1. For the outcome “small for gestational 
age”, birth weight and term of pregnancy were compared using population-based reference 
values from the United States (27). 
 
3.7. Review process and endorsement of other societies 
A draft of the guideline was reviewed by 4 experts in the field (see ‘Acknowledgments’ 




societies and networks were asked to review the guidelines: the European Association of 
Neurosurgical Societies, the Endocrine Society, USA, the European Reference Network on 
Rare Endocrine Conditions (Endo-ERN), and the European Neuroendocrine Association 
(ENEA). Furthermore, patient groups were approached to review the guidelines. All 
comments and suggestions were then discussed and implemented as thought appropriate 
by the panel. 
 
4. Summary and interpretation of the evidence from systematic 
literature reviews 
 
4.1. Clinical question I: What is the safety profile and teratogenicity of medical treatment 
during pregnancy in patients with prolactinoma? 
 
We included 51 studies on medical treatment of prolactinomas during pregnancy (28-78), 
and another 26 studies on medical treatment of hyperprolactinaemia (including patients 
with prolactinomas in mixed populations) (79-104), see Appendix 1 Table 1 for description 
of the GRADE evidence and Appendix 1 Table 2 for details of included studies. In total, 837 
pregnancies in patients with prolactinoma were included, resulting in 762 live infants. For 
hyperprolactinaemia from mixed aetiology, the numbers were 2144 pregnancies, resulting 
in 1873 live infants. Patients used mainly bromocriptine or cabergoline, but also 
(dihydro)ergocryptine, lergotrile, metergoline, and quinagolide during pregnancy. In the 
majority of patients with prolactinoma (553 pregnancies) medical treatment was stopped 
after confirmation of pregnancy (73.2%, 95% confidence interval [CI] 69.9-76.4%). Medical 
treatment was later restarted during pregnancy in 29 out of these 553 patients (5.2%, 95%CI 
3.5-7.4%). A summary of safety and teratogenicity outcomes is shown in Appendix 1 Table 3. 
Of note, not all reported maternal events happened during the use of medication for 
prolactinoma or hyperprolactinaemia. No formal control groups were included, hampering 
firm conclusions. 
There was one reported neonatal death after use of cabergoline for prolactinoma during 
pregnancy (no further data on duration or timing of treatment was provided). There were 




pregnancy, all of whom after treatment with bromocriptine (no further data provided). In 
women with prolactinomas there were 17 infants with malformations: 6 after use of 
bromocriptine, and 11 after use of cabergoline. Additionally, there were 30 malformations 
after medical treatment of hyperprolactinaemia during pregnancy: 5 after use of 
bromocriptine, and 25 after use of cabergoline. The data did not indicate a higher 
prevalence of congenital malformations after use of medication for prolactinoma (2.2%, 
95%CI 1.3-3.5) or hyperprolactinaemia (2.5%, 95%CI 1.8-3.3) during pregnancy than in the 
general population (2.4% in Europe) (105).  
In addition, safety and teratogenicity outcomes did not clearly differ between bromocriptine 
and cabergoline (see Appendix 1 Table 3). The most commonly reported (maternal) signal 
was the percentage of patients with symptomatic tumour growth (5.4%, 95% CI 3.9-7.1). 
Based on our review of tumour growth during pregnancy (see section 4.4), this was most 
likely observed predominantly in women with macroadenomas. Often, prolactinoma 
medication was restarted in these patients to treat symptoms of tumour progression.  
 
4.2. Clinical question II: What is the safety profile and teratogenicity of medical treatment 
during pregnancy in patients with acromegaly? 
 
We included 47 studies on medical treatment for acromegaly during pregnancy (55, 106-
151), see Appendix 2 Table 1 for the GRADE evidence and Appendix 2 Table 2 for study 
details. In total, 146 patients were included, who had 159 pregnancies, resulting in 159 live 
infants. Patients used bromocriptine, cabergoline, unspecified dopamine agonists, 
octreotide, lanreotide, pasireotide, unspecified somatostatin analogues, or pegvisomant 
during pregnancy. A summary of safety and teratogenicity outcomes after medical 
treatment for acromegaly during pregnancy is shown in Appendix 2 Table 3. Importantly, 
not all reported maternal events occurred during the use of medication for acromegaly, as 
patients may have used the drugs for a shorter period. We performed subgroup analyses of 
patients using medication until pregnancy confirmation only, and of patients using 
medication during a larger part of pregnancy, i.e. also after pregnancy was confirmed. 
In 79 pregnancies (71%), medical treatment for acromegaly was stopped after confirmation 
of pregnancy. There was one ectopic pregnancy during use of pegvisomant (146). There was 




lanreotide (111). There were two malformations reported: a ureteral stenosis after 
octreotide LAR (2.6% out of 38 octreotide users, 95%CI 0.1-13.8%), and a single kidney after 
bromocriptine use. There was no indication from the data that congenital malformations 
are more prevalent after use of medication for acromegaly during pregnancy (1.3%, 95%CI 
0.2-4.5) than in the general population (2.4% in Europe) (105). There was no clear difference 
in safety or teratogenicity between patients who used medication until confirmation of 
pregnancy only and patients who used medication during a longer period of pregnancy.  
 
4.3. Clinical question III: What is the safety profile and teratogenicity of medical treatment 
during pregnancy in patients with Cushing’s disease? 
 
We included ten studies, reporting on 10 women, with medical treatment for Cushing’s 
disease during pregnancy (152-161), some of which also involved patients with cortisol 
secreting adrenal adenomas. The GRADE evidence table is shown in Appendix 3 Table 1, and 
details of the studies are shown in Appendix 3 Table 2. Patients used metyrapone, 
ketoconazole, mitotane, and cabergoline during pregnancy. Adverse effects were reported 
in six out of ten mothers (60%, 95%CI 26-88%): gestational diabetes mellitus, pre-eclampsia, 
hypothyroidism, no milk for breastfeeding. Seven out of twelve infants (two pairs of twins) 
experienced adverse events (1 neonatal death; low birth weight, small for gestational age, 
pre-term, intensive care treatment), which is 58% (95%CI 28-85%). There were no 
congenital malformations reported. Numbers are too small to draw firm conclusions on 
preferred treatment and teratogenicity, based on published data. 
 
4.4. Clinical question IV: What is the incidence of tumour growth during pregnancy in 
patients with a non-functioning or functioning (Cushing’s disease, acromegaly, or 
prolactinoma) adenoma? 
 
We included one study on tumour growth during pregnancy in non-functioning pituitary 
adenomas (162), 18 studies in patients with prolactinoma (44, 46, 51, 52, 55, 57, 64, 71, 72, 
76, 78, 80, 162-167), and four studies in patients with acromegaly (55, 110, 119, 124); see 
Appendix 4 Table 1 for the GRADE evidence, and Appendix 4 Table 2 for details of included 




functioning pituitary adenoma, the only study reported on 16 pregnancies in 16 patients; for 
prolactinoma, studies reported on 753 pregnancies in 652 patients, with separate data on 
146 microadenomas and 162 macroadenomas. For acromegaly, there were 128 pregnancies 
in 97 patients, with separate data on 17 microadenomas and 106 macroadenomas. There 
were no reported Cushing’s disease cases. 
Average tumour size before and after pregnancy was compared in 4 studies that showed 
unchanged (46), increased (80, 162), or reduced adenoma size (76). For non-functioning 
pituitary adenomas, symptomatic tumour growth (headache or visual defects) occurred in 6 
patients (37.5%, 95%CI 15.2-64.6%) and radiologically confirmed tumour growth as defined 
by the individual studies was seen in 4 patients (25.0%, 95%CI 7.3-52.4%). In prolactinoma, 
symptomatic tumour growth during pregnancy was seen in 52 patients (9.0%, 95%CI 6.8-
11.6%) and radiological tumour growth in 40 (10.6%, 95%CI 7.7-14.2%). For 
microprolactinomas, there were 7 patients with symptomatic tumour growth (15.2%, 95% CI 
6.3-28.9%) and 15 with radiological tumour growth (14.4%, 95%CI 8.3-22.7%). For 
macroprolactinomas, there were 36 patients with symptomatic tumour growth (30.5%, 
95%CI 22.4-39.7%) and nineteen with radiological tumour growth (13.9%, 95%CI 8.6-20.8%). 
In acromegaly, symptomatic tumour growth during pregnancy was seen in 9 patients (7.0%, 
95%CI 3.3-12.9%) while radiological tumour growth occurred in 6 (5.4%, 95%CI 2.0-11.4%). 
For GH-producing microadenomas, 3 patients exhibited symptomatic tumour growth 
(30.0%, 95%CI 6.7-65.2%), and 2 only radiological tumour growth (25.0%, 95%CI 3.2-65.1%); 
however, the low number of patients precludes a firm conclusion regarding the true risk as 
can be seen from the wide confidence intervals. For GH-producing macroadenomas, there 
were 4 patients with symptomatic tumour growth (4.1%, 95%CI 1.1-10.2%), and 3 with 
radiological tumour growth (3.7%, 95%CI 0.8-10.3%). 
 
4.5. Clinical question V: Is pituitary surgery safe for pituitary adenomas during pregnancy? 
 
We included 28 studies on transsphenoidal surgery of pituitary adenomas during pregnancy 
(28, 49, 124, 135, 153, 157, 168-189), see Appendix 5 Table 1 for the GRADE evidence, and 
Appendix 5 Table 2 for study details. Pituitary surgery was performed in 33 cases during 
pregnancy. The vast majority of patients had hormone secreting macroadenomas (Appendix 




trimester. The indications for surgery mainly included active Cushing disease, visual 
deterioration related to tumour growth or apoplexy. Surgery provided symptom relief in 25 
cases out of 28 in whom effectiveness was reported (89.3%, 95%CI 71.8-97.7%). In total, 
nine women experienced surgery-related adverse events (diabetes insipidus, SIADH, 
cerebrospinal fluid leakage). This high percentage of adverse events might be related to the 
special indication for pituitary surgery in pregnancy being restricted to emergency 
situations. In total, nine infants showed adverse outcomes in the course of pregnancy 
(28.1%; 95%CI 13.7-46.7%). There was one miscarriage soon after surgery during the second 
trimester. Furthermore, there was one intrauterine death, and two cases of neonatal death 
not directly after surgery. Most adverse outcomes for infants occurred in mothers with 
Cushing’s disease (eight out of nine infants with adverse events). 
 
 
5. Recommendations and Rationale for the recommendations  
 
5.1. General recommendations: Preconception stage 
 
R.1.1. We recommend that women of reproductive age with a diagnosis of a pituitary 




Pituitary function might be impaired due to compression by or hormonal hypersecretion 
from the pituitary adenoma. In addition, side effects of medical therapy for the mother and 
foetus should be taken into account and discussed with women of reproductive age. In 
women with hypopituitarism, replacement therapy should be optimized, and assisted 
reproductive technologies (ART) should be discussed when appropriate. Women should be 
given relevant information about their chances of fertility and pregnancy depending on their 
diagnosis (see respective recommendations for each adenoma). Timing of pregnancy should 
be discussed and women should be encouraged to plan pregnancy after control of the 




consultation should take place with a team that should include an endocrinologist, an 
obstetrician with expertise in managing high risk pregnancies for maternal indications and, 
in case of large pituitary adenomas, a dedicated pituitary neurosurgeon. 
 
R.1.2. We recommend that women of reproductive age with a diagnosis of pituitary 




The consulting endocrinologist should inform women seeking pregnancy that this is feasible 
in the majority of cases, that the outcome is generally good and that breast feeding is often 
possible (see respective recommendations for the different adenoma types and therapies). 
At the same time, it should be stressed that pregnancy constitutes a medical situation 
where expert knowledge and often collaboration between specialists from different fields is 
required. The woman’s age is a major determinant of fertility and pre-conception 
counselling should also include an obstetrician with expertise in maternal-fetal medicine 
and reproductive medicine. An endocrine work-up including all anterior pituitary functions 
should be performed (see Table 2), with special attention to possible associated metabolic 
or cardiovascular diseases.  
 
R.1.3. We recommend that management of women of reproductive age with a large 
pituitary adenoma (>1cm), Cushing’s disease or acromegaly, who consider pregnancy, be 
discussed in a multidisciplinary team.  
 
Rationale 
Due to possible compressive effects of macroadenomas, which may enlarge during 
pregnancy and possible adverse effects of therapies necessary to control size or function of 
pituitary adenomas, we advise discussing such patients in a multidisciplinary team including 
an endocrinologist, an obstetrician, a pituitary neurosurgeon and in some cases a 
neuroradiologist, a neuro-ophthalmologist and a reproductive endocrinologist. Compression 
of the optic chiasm with visual field impairment is an indication for pre-pregnancy pituitary 




women with a non-functioning pituitary macroadenoma and no visual field impairment, 
who are seeking pregnancy, the decision to operate prior to planned pregnancy may also 
take into account the presence of gonadotrophin deficiency (191) as surgery provides 
pituitary recovery in about 30% of cases (192, 193), in particular normalization of ACTH, 
cortisol and PRL (194). The surgical risk of a postoperative gonadotrophin deficiency and 
also a panhypopituitarism (14% (195)), which could impact on pregnancy course should be 
considered, and should be taken into account for the surgical decision. 
 
R.1.4. We recommend that in women with a diagnosis of pituitary adenoma and 




In women with hypopituitarism, reported fertility rates range from 47% to 76%, and reached 
over 80% in women with isolated hypogonadotropic hypogonadism after ART (196, 197). 
Women with childhood onset of hypopituitarism have much lower fertility rates (196-199). 
The pre-conception consultation should include diagnosis of any pituitary deficiencies (see 
R.1.2.), initiation and optimisation of the replacement therapy aiming for mid-normal 
reference range values. The importance of adherence to treatment should be emphasised in 
relation to pregnancy outcomes and fetal health. Women with hypopituitarism and optimal 
replacement therapy often require ART (196, 200, 201), but in the absence of 
gonadotrophin deficiency they may conceive spontaneously (201, 202). Initiation and 
optimisation of GH replacement for at least 3 months prior to conception has been shown 
to improve the success rate of ART and ovulation stimulation (OS) in women with 
concomitant gonadotrophin deficiency (199, 203-205). Even though pituitary hormone 
deficiency beyond gonadotropins has been correlated with reduced pregnancy rate and 
outcome, patients with hypopituitarism can be reassured that in vitro fertilisation (IVF) 
treatment is often successful (206).  
Pituitary apoplexy occurring after the application of triptorelin, a GnRH analogue used for 
OS, has been described (207, 208), possibly due to previously undetected 
gonadotropinomas. It should be highlighted that although fertility outcomes and pregnancy 




require multiple OS and/or ART cycles to achieve a live birth and the “take home baby rate” 
per cycle remains reduced (197, 201, 209).  
 
5.2. General recommendations: pregnancy 
 
R.2.1. We recommend that pregnant women with known pituitary adenoma, in particular 
those with a large pituitary adenoma (>1cm), Cushing’s disease or acromegaly, and those 
with pituitary deficiencies, should be followed by an endocrinologist and an advanced nurse 




Pituitary adenomas may cause hypopituitarism, visual impairment or nerve palsies during 
pregnancy and therefore need special surveillance by an expert endocrinologist. 
Individualized management is needed throughout pregnancy, the frequency of 
consultations is determined by the clinical situation, and in uneventful cases, consultations 
can be limited. In patients with acromegaly and Cushing’s disease, special attention to 
glucose homeostasis and blood pressure is needed. Patients with a microprolactinoma or a 
nonfunctioning microadenoma will only need consultation with an endocrinologist during 
pregnancy if new symptoms such as headache or visual symptoms occur. 
 
R.2.2. We recommend that pregnant women with diagnosed hypopituitarism should have 
regular clinical and hormonal follow-up by an endocrinologist and an advanced nurse 
practitioner where relevant.  
 
Rationale 
Women with pituitary adenomas and hypopituitarism require regular follow-up at least 
every trimester to monitor for adequate substitution doses and/or to identify signs or 
symptoms of any newly developed pituitary insufficiencies or complications associated with 
functioning adenomas, mainly GH or ACTH-producing (196, 200, 210, 211).   
Patients on levothyroxine replacement therapy might require an increase in dose of up to 




reliable in patients with pituitary disorders (11, 212). Adequate dose should be checked 
during the first and second trimesters using gestational phase- and assay-specific reference 
values (13). Whereas an interval of 4-6 weeks has been suggested for fT4 measurement 
throughout pregnancy (200), not all members of this Clinical Guideline Committee monitor 
their patients that frequently. 
In women with adrenal insufficiency, there is usually no need to alter the doses of 
glucocorticoid replacement therapy during the first half of pregnancy, but an increase by 20-
40% may be needed from week 22-24 onwards, since free cortisol increases during this 
period in healthy women. Hydrocortisone is the preferred choice for glucocorticoid 
replacement during pregnancy; prednisone is also an option as it does not cross the 
placenta. Only 10-12% of the maternal prednisolone concentration reaches the foetus (213). 
Dexamethasone should be avoided because it is insufficiently inactivated by placental 11β-
HSD2 and may therefore cause harm to the foetus (196, 200, 210, 211, 214).  
The desmopressin dose might need to be increased during the third trimester due to 
placental vasopressinase activity and the patient should be informed that in case of polyuria 
and increase of desmopressin, serum sodium concentration should be checked to avoid 
hyponatraemia. Administration of desmopressin appears to be otherwise safe in pregnancy 
(19, 215). 
GH replacement is usually stopped after conception or by the end of the first trimester; the 
benefit-risk balance for GH in pregnancy cannot be assessed (196, 200). Furthermore, large 
amounts of GH are secreted by the placenta during pregnancy. One large observational 
study revealed no relationship between GH replacement therapy regimens and pregnancy 
outcomes (216).  
 
R.2.3. We recommend that women and their partners be provided with education for 
glucocorticoid stress dose adjustment and measures on how to prevent or manage adrenal 
crisis during pregnancy.  
 
Rationale 
Symptoms such as persistent nausea, hyperemesis, and excessive fatigue are common in 
pregnancy. These can also be triggers or symptoms of the onset of an adrenal crisis and 




dosage of hydrocortisone (sick day rules), access to a hydrocortisone injection kit and 
glucocorticoid emergency card, and training on self-injecting are crucial to prevent and 
promptly manage an adrenal crisis. In case of an adrenal crisis, fluid replacement (best with 
0.9% saline IV) and immediate parenteral administration of hydrocortisone 100 mg (IV, IM, 
SC) are potentially life-saving for the mother (200, 210, 214, 217). Fetal monitoring by 
cardiotocography (CTG) and ultrasound is also necessary to ensure the well-being of the 
unborn child.  
 
R.2.4. We recommend performing an MRI without contrast in pregnancy in case of 
symptoms of tumour progression or apoplexy.  
 
Rationale 
MRI is considered safe in pregnancy and should be used in symptomatic patients with 
impairment of visual fields or visual acuity, cranial nerve palsies or severe headache usually 
after neuro-ophthalmologic evaluation. Gadolinium can cross the placenta and reach the 
fetal circulation (218-221), its use is therefore to be avoided in most cases, especially in the 
first trimester. Relevant information can usually be obtained by unenhanced T1 and T2 
weighted sequences. Routine MRI follow-up during pregnancy is not recommended.  
 
R.2.5. We recommend that neuro-ophthalmologic examination in pregnancy be performed 
for adenomas impinging visual pathways or in case of suspected tumour progression or 
pituitary apoplexy.  
 
Rationale 
Due to the possible risk of tumour impingement of the visual pathways, a neuro-
ophthalmologic evaluation including determination of visual acuity, visual fields and, if 
available, optical coherence tomography (OCT) analysing retinal nerve fibre layer (RNFL) and 
ganglion cell complex (GCC) should be performed in symptomatic patients, which will aid 
the decision about whether a MRI is indicated. Women with pituitary adenomas larger than 
1 cm not previously treated with surgery or radiotherapy are at increased risk of visual field 
impairment during pregnancy (222). Together with the results of endocrine function and 




frequency of neuro-ophthalmologic evaluations will be determined by signs and symptoms 
as well as by results of prior examinations. 
 
R.2.6. We recommend considering surgery in pregnant women with deterioration of vision, 
ophthalmoplegia or severe headache attributable to tumour enlargement if medical tumour 
treatment is unfeasible or ineffective ().  
 
Rationale  
In situations with chiasmal compression and severe loss of vision (impairment of visual 
acuity or OCT or severe visual field impairment) surgical decompression should be 
considered even if there is no detectable radiological enlargement of the tumour (191, 223, 
224). Surgery provided symptom relief in 89.3% (95%CI 71.8-97.7%), see 4.5 for details. In 
case of other cranial nerve palsies or headache occurrence, particularly related to apoplexy, 
surgical resection should be individually discussed. 
 
R.2.7. If surgery is indicated, we suggest to perform transsphenoidal surgery in the second 
trimester if the clinical course allows this (). 
 
Rationale  
Surgical indications for pituitary tumours are rare during pregnancy and surgery should 
generally be avoided. In cases of symptomatic tumour enlargement during pregnancy, 
medical treatment with dopamine agonists or somatostatin analogues may be attempted 
before undertaking transsphenoidal surgery. Severe visual disturbance related to pituitary 
apoplexy or tumour growth, and uncontrolled Cushing’s disease are the main surgical 
indications during pregnancy.  
There are no guidelines on transsphenoidal surgery in pregnancy. Evidence comes from 
small series (see 4.5) (223). The majority of cases published had surgery in the second 
trimester. The first trimester should be avoided if possible (225, 226). In the third trimester, 
preterm delivery before non-obstetrical surgery should be considered. Emergency 
operations (e.g. severe loss of vision or ophthalmoplegia) must be considered and 
performed at any time during pregnancy preferably in expert pituitary centers, including 




statements are supported by the neurosurgical literature on meningioma management 
during pregnancy (223, 227). 
 
R.2.8. We recommend not to perform radiotherapy during pregnancy. 
 
Rationale 
Radiotherapeutical interventions are inappropriate during pregnancy due to their delay in 
the onset of effects and potential harm to the foetus. 
 
5.3. General recommendations: Delivery and breastfeeding 
 
R.3.1. We suggest that pregnant women with pituitary adenomas should receive standard 
obstetrical care but recommend close maternal and fetal surveillance. 
 
Rationale  
A systematic review of 31 pregnancy outcomes in women with hypopituitarism found no 
neonatal complications or congenital anomalies in the newborns. However, these women 
had higher rates of Caesarean deliveries, transverse lie and small for gestational age 
neonates compared to controls (228). A recent study showed that women with non-
functioning adenomas were more likely to have Caesarean delivery compared to controls 
(relative risk 2.06, 95%CI 1.26-3.36). There was no solid evidence that pituitary tumours 
were associated with adverse pregnancy outcomes such as pregnancy-induced 
hypertension, pre-eclampsia, pre-term labour or still birth (162). Women should be 
informed early on in their pregnancy about the possibility of Caesarean delivery. 
Special monitoring of the newborns for the risk of hypoglycaemia is needed in case of 
maternal hyperglycaemia and/or hypertension, disorders that may occur in GH and ACTH 
secreting pituitary adenomas (110). In rare pregnancies with Cushing’s disease, the risk for 
prematurity and intrauterine growth restriction is elevated and there were individual 
reports of coarctation of the aorta, transient neonatal jaundice, hypoglycaemia and adrenal 
insufficiency requiring temporary treatment with hydrocortisone (157).  
In women with ACTH deficiency, hydrocortisone stress dosing is recommended during 




should be initiated at the onset of active labour for vaginal delivery or pre-operatively for a 
Caesarian section. While it has been suggested that this should be followed immediately by 
a continuous intravenous infusion of hydrocortisone 200 mg/24 hours throughout labour for 
both vaginal delivery or Caesarian section (200, 210, 229), most members of this Clinical 
Guideline Committee are using lower doses. After delivery, the pregnancy hydrocortisone 
dose should be gradually tapered down to the pre-pregnancy dose (200, 210, 214, 217). 
 
R.3.2. In general, breastfeeding is feasible and not contra-indicated.  
 
Rationale 
Individual concerns such as the need to control tumour size and activity as well as type of 
drug therapy employed need to be considered, please see specific chapters and list of drugs 
used for the treatment of pituitary adenomas (Appendix 6).  
 
 
5.4. Nonfunctioning adenomas (NFAs) 
 
In women with NFAs diagnosed prior to pregnancy, the general recommendations for the 
preconception stage, pregnancy, delivery and breastfeeding apply (see chapters 5.1-5.3).  
 
R.4.1. In women with a NFA near the optic chiasm who are planning a pregnancy, surgery 
may be considered to reduce the risk of chiasmal compression and to enhance fertility. 
 
Rationale 
As the pituitary gland expands during pregnancy, surgery should be considered on the basis 
of NFA size and proximity to the optic pathways (see R.1.3.). Additionally, it has been 
suggested that for women with a macroadenoma and no visual field impairment, who plan 
pregnancy, surgery may be considered in order to optimize fertility (191), since surgery 
provides recovery of hypopituitarism in about 30% (192). The risk of postoperative pituitary 
deficiency, which is estimated around 14% (195) should be integrated in the surgical 





R.4.2. We suggest that for women with intrasellar nonfunctioning microadenomas and an 




The majority of previously treated NFAs do not enlarge during pregnancy (55, 162, 222). A 
study monitored 65 women with treatment naïve pituitary adenomas during 111 
pregnancies; none of the patients with a microadenoma developed visual impairment after 
up to four full-term pregnancies (222). Additionally, new onset pituitary hormone 
deficiencies are unlikely. 
 
R.4.3. We recommend that for macroadenomas and/or extrasellar NFAs, neuro-
ophthalmologic and, if indicated, MRI examination should be performed only in case of 
symptoms of tumour progression or pituitary apoplexy during pregnancy. 
 
Rationale  
In contrast to microadenomas, six of eight primiparous patients with macroadenomas 
(range 1.2 - 2.5 cm) in the above mentioned study developed visual field impairment (222). 
In case of macroadenomas in contact or close to the chiasm, systematic visual examination 
should be considered. Visual examination frequency and type of tests (with or without 
optical coherence tomography) depend on the local practices and should be adapted case 
by case. 
 
R.4.4. We recommend that in case of a clinical need to reduce adenoma volume during 
pregnancy, surgery is the preferred option (). 
 
Rationale 
The main indication for pituitary surgery during pregnancy is to protect visual function (191, 
223, 224). A trial with cabergoline might be considered. Apoplexy is another rare but acute 
condition in a patient with NFA that may require surgical intervention. If possible, the first 
trimester should be avoided and in the third trimester preterm delivery should be 





R.4.5. We recommend awaiting re-assessment of pituitary imaging and function until after 
delivery and breastfeeding.  
 
Rationale 
A de novo radiological diagnosis of a pituitary mass lesion during pregnancy is usually based 
on symptomatic visual field defects and/or pituitary apoplexy. Before making a NFA 
diagnosis, other diagnoses should be excluded, e.g. CD, acromegaly, prolactinomas, 
hypophysitis. Re-assessment of pituitary imaging and function should be done between 3 
and 6 months after delivery, preferably after breastfeeding but definitely before planning a 




A prolactinoma is expected to be present in 1/500 women of reproductive age (230) and is 
frequently associated with infertility (25, 231). Very high prolactin levels will usually cause 
amenorrhoea, while milder degrees of hyperprolactinaemia may cause oligomenorrhoea or 
luteal phase insufficiency (232). Furthermore, in the presence of regular cycles, abnormal 
prolactin concentrations might alter hormonal conditions for adequate embryo 
implantation (230). 
 
R.5.1. We recommend treating women with a prolactinoma, who are actively seeking 
pregnancy, with a dopamine agonist and strive for normalization of prolactin concentrations 
and restoration of regular ovulatory cycles (). 
 
Rationale 
In agreement with guidelines from both the Pituitary Society and the Endocrine Society, we 
consider a desire for pregnancy as an indication for strict prolactin normalization in young 
women with a prolactinoma, even in those with mild hyperprolactinaemia and apparently 
regular normal cycles (232, 233). It is important to inform patients that restoration of 




before normal menses return (25, 234) and to counsel patients whether prompt conception 
is safe. 
 
R.5.2. We recommend medical treatment as first choice therapy for women with a 
prolactinoma and actively seeking pregnancy; transsphenoidal surgery can be considered in 
individual cases (). 
 
Rationale  
Dopamine agonists (DA) are the standard treatment for women in reproductive age with a 
micro- or a macroprolactinoma, restoring ovulation in 80-90% (234, 235). Few studies have 
directly compared the currently available DA in their efficacy to allow gestation (236). We 
suggest using cabergoline because it is better tolerated and has a higher efficacy than 
bromocriptine in both normalizing prolactin levels (63, 232, 237, 238) and inducing pituitary 
tumour shrinkage (232, 235, 239). Transsphenoidal adenomectomy is an option in selected 
cases (25, 230) such as intolerance or resistance to DA or personal preference. It is 
considered less efficient than medical therapy, leading in expert hands to a sustained 
normalization of prolactin levels in 70–80% of microadenomas, but only in 30–40% of 
macroadenomas (240, 241). However, in macroprolactinomas (25, 232, 233) it might reduce 
the risk of tumour enlargement during a subsequent pregnancy (25) and optimize the 
chances of prolactin normalization with subsequent DA treatment (242). The risk of 
postoperative pituitary deficiency remains very limited (240, 243). 
 
R.5.3. We recommend cabergoline as medical treatment at the lowest possible effective 
dose until pregnancy is confirmed (). 
 
Rationale  
Treatment with dopamine agonists should not be withdrawn in women seeking pregnancy 
and, as discussed above, due to its higher efficacy and better tolerance, cabergoline is 
considered first choice in this population (232, 235).  
We performed a systematic review of reports published until 2019 on pregnancies initiated 
under cabergoline treatment (n=1272), of which some patients used cabergoline during a 




miscarriage (9.0%), pre-term delivery (8.0%) and neonatal malformations (3.3%) are similar 
to those reported for bromocriptine and do not clearly deviate from those reported in an 
age-matched population not on DA therapy (80, 244, 245). While some follow-up studies of 
children for up to 12 years after foetal exposure to cabergoline do not suggest an increased 
risk of developmental and or/metabolic abnormalities (25, 80, 230), one study with a follow-
up of 61 children of up to 16 years reported 2 children who developed epilepsy (one after 
distress at birth because of abruptio placentae) and 2 with a pervasive developmental 
disorder (83). However, the relationship of such disorders with previous cabergoline 
exposure cannot be proven. 
Regarding the use of quinagolide, the manufacturer’s data include 176 pregnancies, in 
which this drug was given for a median duration of 7 weeks; 24 spontaneous abortions, 1 
stillbirth and 9 foetal malformations were reported (246). Thus, quinagolide appears to be 
less safe during pregnancy, although the available data are limited. 
 
R.5.4. We recommend stopping the dopamine agonist once pregnancy is established. 




DA cross the placental barrier and, although the use of bromocriptine and cabergoline has 
not been associated with increased teratogenicity (see 4.1), it is recommended to 
discontinue treatment as soon as pregnancy is confirmed (25, 232, 233).  
For women with a macroprolactinoma close to the optic chiasm, it should be confirmed that 
tumour volume has shrunk substantially prior to conception (25). After shrinkage, it is 
generally safe to discontinue DA. If adenoma size is not controlled, several options are 
available. First, DA therapy seems to be safe and in special circumstances can be continued 
throughout the pregnancy, particularly if the adenoma is abutting the optic chiasm. Second, 
DA can be started later in pregnancy in case of symptomatic tumour growth (see R.5.8.). 
Cabergoline is slightly preferable due to its better tolerability, higher efficacy and longer 
duration of action. Alternatively, partial or complete resection by transsphenoidal surgery 
prior to conception can be considered, in particular for cystic lesions that are often 




one study showed that a large proportion of cystic tumours can also be reduced by DA 
(247). 
Limited safety data are available regarding the use of bromocriptine throughout gestation in 
mothers with hyperprolactinaemia (n=36 pregnancies and n=36 live infants) with no 
abnormalities noted in the infants except for one balanced translocation of chromosomes 8 
and 12 (50), and one case of testicular ectopy, which corrected spontaneously after 7 
months (57). The record is even smaller for cabergoline used throughout gestation (n=34 
pregnancies and n=26 live infants), with no recorded malformations in live infants. There 
was one fetal death at week 34 in a mother suffering from severe pre-eclampsia (34). A 
report on 25 pregnancies from India with cabergoline therapy throughout pregnancy 
showed one fetal death, 3 missed abortions, 3 pregnancy terminations due to major 
congenital malformations, 2 premature deliveries and 18 live infants (64). 
 
R.5.5. We recommend not measuring prolactin during pregnancy. 
 
Rationale  
Pregnancy is associated with a physiological elevation of prolactin concentrations (248, 249) 
and serum prolactin levels may increase about 10-fold throughout pregnancy, reaching 
levels of 150-300 µg/L at term (250-252). A similar prolactin secretory pattern is usually seen 
in pregnant women with a prolactinoma, often with a greater amplitude (25). However, in 
some prolactinoma patients, serum prolactin levels may not increase further during 
pregnancy and prolactin is therefore not a reliable marker of eventual tumour progression 
(25, 253). Therefore, we do not recommend prolactin measurements during gestation in 
prolactinoma patients. Furthermore, serum prolactin concentrations do not reliably predict 
the likelihood of normal breastfeeding (254).  
 
R.5.6. We suggest that for women with a small intrasellar microprolactinoma, and normal 







Data are few regarding development of pituitary deficiencies during pregnancy in women 
with prolactinomas. In a study including 83 patients with prolactinoma, two patients 
developed TSH deficiency and one developed ACTH deficiency during pregnancy. All three 
had a macroadenoma and tumour growth was observed in two of them (55). Thus, in 
women with a microprolactinoma routine endocrine care is not mandatory and 
endocrinologists should be consulted only in case of symptoms or signs suggesting tumour 
growth or new onset hypopituitarism. 
  
R.5.7. We suggest careful and regular monitoring for tumour growth in pregnant women 
with a large macroprolactinoma or a prolactinoma close to the optic chiasm ().  
 
Rationale  
Overall, symptomatic tumour growth during pregnancy occurs in 9.0% (95%CI 6.8-11.6%) of 
prolactinomas. However, in women with a macroprolactinoma, the risk is reported to be 
considerably higher, 30.5% (95% CI 22.4-39.7%), see section 4.4. A much smaller risk – 
between 1 and 4% – was observed in cases where the tumour had been operated, irradiated 
or sufficiently reduced by prolonged DA therapy before pregnancy (25, 36, 51, 76, 165). 
Data on 85 viable pregnancies in 46 patients with a macroprolactinoma demonstrated 
tumour growth-related symptoms 12 times in 9 patients (19.6%) including 3 cases of 
apoplexy (255).  
Therefore, we recommend careful individualised follow-up with clinical evaluation, including 
visual field testing, visual acuity, OCT and in case of visual deterioration MRI assessment 
without gadolinium in pregnant women with a macroadenoma which could not be 
sufficiently reduced by prior treatment.  
 
R.5.8. We recommend to consider restarting dopamine agonists in pregnancy in case of 
symptoms of progressive prolactinoma growth. Surgery should be used only in case of 
medical failure or symptomatic apoplexy (). 
 
Rationale 
In case of symptomatic prolactinoma growth during pregnancy, restarting DA is effective in 




preferable in terms of side effects and efficacy, the doses in pregnant women are similar to 
those in non-pregnant women and the lowest possible dose should be used.  
Transsphenoidal surgery is indicated if medical treatment fails to rapidly induce sufficient 
tumour shrinkage and symptom relief. Rapid decompressive surgery is also indicated in 
many cases of progressively symptomatic pituitary apoplexy (181, 223), which may cause 
severe visual defects. In case of sudden and severe headache, ophthalmoplegia or limited 
visual field impairment, surgery should be discussed case-by-case (255). It may occur both in 
patients treated with DA (64) and in untreated pregnant women with a prolactinoma (247). 
However, haemorrhagic necrosis of a macroprolactinoma during pregnancy may also be 
minor or asymptomatic, thus not requiring surgery and having a favourable outcome 
without treatment (230).  
 
R.5.9. For women with a prolactinoma, breastfeeding is usually feasible and not contra-




Lactation is considered safe and feasible. It is also considered safe to withhold DA treatment 
as long as breastfeeding is desired (81, 230). In individual cases of macroadenoma requiring 
DA throughout pregnancy, the advice to breastfeed and stop DA should be individualized 
(256). Breastfeeding while taking a DA is not possible and should be avoided anyway.  
 
R.5.10. We recommend reassessing prolactinoma status after every pregnancy before 
considering restarting therapy. 
 
Rationale 
There is a subset of prolactinomas that will involute during the pregnancy and lactation. In 
various studies, these percentages range from 17-68%, on average 40% for a median time of 
22 months (46). There is a higher number of remission in microprolactinomas (46%) than 
macroprolactinomas (26%). Biochemical remission may coincide with tumour 




recommend re-evaluating the status of the prolactinoma 1 to 3 months after the lactation 
period, with clinical assessment, prolactin measurement, and MRI in cases of previous 
macroadenomas. In case of remission, we recommend clinical and hormonal follow-up at 6 
months and yearly thereafter, since recurrence may occur in up to 65% of cases.  
 
5.6. Acromegaly 
Acromegaly may be associated with infertility, through several mechanisms (257), including 
hypopituitarism and hyperprolactinaemia related to a mixed GH-PRL-secreting adenoma or 
to pituitary stalk compression. Moreover, excess GH/IGF-I secretion may have a direct effect 
on hypothalamic gonadotropin-releasing hormone (GnRH) secretion or induce polycystic 
ovary disease-like conditions. 
 
R.6.1. In women with acromegaly considering pregnancy, we recommend assessment of 
disease activity, comorbidities and fertility status. 
 
Rationale  
Impaired glucose tolerance, diabetes mellitus and hypertension associated with active 
acromegaly (258) may worsen in pregnancy and thereby harm the foetus (110, 116, 124, 
147). Therefore, control of acromegaly and its complications is recommended in women 
with acromegaly who wish to conceive. Glucose tolerance and blood pressure should be 
monitored during pregnancy. Tumour mass effect may also be a concern during pregnancy 
and needs to be carefully evaluated before pregnancy to determine appropriate treatment 
(see Table 2).  
 
R.6.2. In women with newly diagnosed acromegaly seeking pregnancy, surgery is 
recommended as first line therapy. 
 
Rationale 
Surgery is first line treatment in newly diagnosed women with acromegaly seeking 
pregnancy (259). If complete removal of the tumour is not feasible, debulking surgery is 




function (even if the risk of growth during pregnancy is very low) (260). Decision making and 
intervention should take place in expert pituitary centers, including Pituitary Tumor Centers 
of Excellence/Endo-ERN Reference Centers . 
 
R.6.3. In women with mild acromegaly, no comorbid conditions and regular ovulatory cycles, 




In patients with mildly elevated IGF-I levels, either newly diagnosed or after surgical 
treatment, maternal IGF-I levels usually decrease during pregnancy as the high oestrogen 
levels induce hepatic resistance to GH (110, 116, 119, 124) and some patients may 
experience symptom relief during the first half of pregnancy (260). This, along with the very 
low risk of symptomatic tumour growth (7.0%, 95% CI 3.3-12.9%, see section 4.4), allows 
postponement or withdrawal medical or surgical treatment until after delivery unless the 
mass lesion demands treatment (260). On the other hand, in case of infertility, even if cycles 
are regular and PRL levels are normal, treatment of acromegaly may be useful to restore 
fertility (257). 
 
R.6.4. We suggest that for women with acromegaly seeking pregnancy and who have an 
indication for medical treatment, somatostatin analogues or cabergoline can be used until 
confirmation of pregnancy if surgery is not an option. Pegvisomant should be reserved for 
selected uncontrolled cases (). 
 
Rationale 
If complete surgical removal of the adenoma is unfeasible (261), primary medical therapy 
may be considered even though no drug is approved by either EMA or FDA for the 
treatment of acromegaly during pregnancy. The potential risks of using these drugs must be 
weighed against their benefit for fertility and disease control. For more information see links 





In the available literature, there is no clear indication that treatment with cabergoline, 
octreotide or lanreotide during pregnancy increases adverse events for mother or child. 
Specifically, treatment with cabergoline and first-generation somatostatin analogues does 
not result in increased prevalence of congenital malformations (see section 4.2) (260). In 
71% of the patients, first generation somatostatin analogue treatment was stopped before 
the end of the first trimester; a smaller number of patients continued treatment throughout 
pregnancy. Pregnancy was usually uneventful, and most women delivered healthy babies of 
appropriate height and weight at term, apart from one case of a large newborn (260). Lastly, 
no excess teratogenic risk of octreotide and lanreotide was reported, but the number of 
exposed pregnancies was too low to allow firm conclusion about the safety of these drugs. 
Despite their different category classification by FDA (see links in appendix 6), there is no 
evidence for preferring octreotide to lanreotide. There are insufficient data about 
pasireotide use in pregnancy to make any recommendation about this 2nd generation 
somatostatin receptor ligand. The Endocrine Society guideline suggests withdrawal of depot 
somatostatin analogue 2 months prior to conception and to switch to short acting 
octreotide (261). With the reassuring safety data reported in this guideline, continuation of 
depot first generation somatostatin analogues up to confirmation of pregnancy may 
however be acceptable and preferred by patients.  
The experience with pegvisomant is limited. Data on 35 pregnancies (27 involving maternal 
and eight paternal pegvisomant exposures) in which pegvisomant treatment of the mother 
was interrupted as soon as the pregnancy was diagnosed, do not suggest adverse 
consequences of pegvisomant on pregnancy outcome (146). Data are however too limited 
to recommend this treatment during pregnancy, unless no other therapy controls severe 
symptoms of acromegaly. 
 
R.6.5. We recommend to consider stopping drugs for acromegaly once pregnancy is 
established ().  
 
Rationale 
There is no indication based on available literature that treatment with cabergoline, 
octreotide or lanreotide during pregnancy results in more congenital malformations (1.3%) 




data on the safety of octreotide, lanreotide or pegvisomant are limited, women of 
childbearing age who receive these drugs should discontinue the treatment when 
pregnancy is confirmed as a safety precaution. Since the high oestrogen levels during 
pregnancy induce GH resistance, acromegaly symptoms tend to improve, and stopping 
drugs is generally regarded as safe. Only severe headache, serious endocrine symptoms or 
tumour volume issues may require reinstitution of drugs. In the infrequent cases when this 
is needed, we suggest to start dose titration with short acting sc octreotide aiming at the 
lowest possible effective dose.  
 
R.6.6. We recommend not to measure GH and IGF-I during pregnancy. 
 
Rationale  
During normal pregnancy the placenta produces a GH variant (hPGH) (262), which cross-
reacts with pituitary GH in most immunoassays (263). During the first trimester of normal 
pregnancy, maternal IGF-I levels decrease by about 30% (264) and thereafter may increase 
to reach a peak at 37 weeks of gestation that is two-fold elevated as compared to the pre-
pregnancy level (265); in some cases this peak is not observed (110, 116, 119, 124). Taken 
together, measurements of serum GH and IGF-I levels do not provide useful clinical 
information and are therefore not recommended (261).  
 
R.6.7. We suggest that for pregnant women with large adenomas, or adenomas close to the 




During normal pregnancy, the pituitary size may increase by up to 45% during the first 
trimester, which may predispose to compressive symptoms (222). It is unclear if pregnancy 
may trigger growth of a pre-existing GH-secreting pituitary adenoma, but discontinuation of 
somatostatin analogue treatment may allow regrowth of the tumour (113, 126). Overall, 
symptomatic tumour growth during pregnancy in acromegaly is seen in 7.0% of patients 
(95% CI 3.3-12.9%), see section 4.4. Development of visual field defects during pregnancy is 




neuroophthalmological evaluation and - in case of visual impairment - MRI without contrast 
is indicated.  
 
R.6.8. We suggest to consider starting or restarting medical treatment for tumour control 
and severe clinical symptoms attributable to acromegaly ().  
 
Rationale 
Medical treatment with octreotide or lanreotide is suggested as first line treatment in the 
event of symptomatic tumour enlargement with visual loss or neurological complications, 
even though surgery in the second trimester in general is considered safe (223). Medical 
treatment with DA has also been used but is probably less effective (110, 117, 118, 122, 124, 
143, 150, 266). The duration of the treatment depends on the severity of symptoms and 
some patients have been treated throughout with dopamine agonists or first generation 
somatostatin analogues (260). Treatment of hyperglycaemia and hypertension should follow 
general guidelines for pregnant women (110, 116, 147).  
 
R.6.9. In acromegaly, breastfeeding is feasible and not contra-indicated, but we recommend 
to take individual circumstances like drug use and disease activity into account. 
 
Rationale 
Breastfeeding is generally possible and not contraindicated (106, 110-113, 116, 139). As a 
safety principle, somatostatin analogues and pegvisomant should be avoided in nursing 
mothers.  
 
R.6.10. We recommend re-assessing disease activity after pregnancy.  
 
Rationale 
Shortly after delivery, a rebound of disease activity is frequently observed (110, 116, 124, 
126, 139, 267); therefore early resumption of treatment may be indicated. A postpartum 
MRI should be performed in most patients with a previously documented adenoma, timing 
depending on disease severity, and known remnant. Gadolinium should not be used if the 






5.7. Cushing’s disease 
 
Although this Guideline is focused on pituitary tumours and pregnancy, it is important to 
note that published data often include adrenal as well as pituitary cases of Cushing’s 
syndrome (CS), and that hypercortisolism from any source may have a significant negative 
impact on the mother and foetus. Hypercortisolism leads to hypogonadism and infertility; 
thus, pregnancy in CD is very rare. When women with CS do become pregnant, it is most 
often of adrenal origin (60% of cases) (26). This is in contrast to non-pregnant women, 
where CD is responsible for 70% of the cases.  
 




Pregnancy should be avoided in the presence of Cushing’s syndrome of any aetiology, given 
the increased incidence of both maternal and foetal complications (18, 26, 268). Women 
with active CS show a high incidence of preterm deliveries, probably due to more frequent 
complications during pregnancy such as gestational diabetes mellitus, hypertension or 
preeclampsia; additionally, a higher rate of Caesarean section in comparison to cured CS is 
reported (51.7 vs. 21.9 %) (26). Foetal risks are also higher, and include deaths, preterm 
births, neonatal infections, hypoglycaemia, and respiratory distress. Foetal loss is higher in 
non-treated mothers (30.6% of cases), but also increased in women treated during 
pregnancy, either medically (20.8%) or surgically (12.5%). Other major foetal morbidities are 
preterm delivery (66.3% in untreated patients, 76.2% if treated medically, 56.1% if treated 
surgically during pregnancy) and low birth weight (68.3%, 68.8% and 73.3%, respectively) 
(18). 
When foetal loss and global foetal morbidity are compared between active and cured CS, 
both are much higher in active disease (23.6 vs. 8.5% and 33.3 vs. 4.9%, respectively). In 
cured CS, both maternal and foetal risks tend to normalize. Prior obstetric complications are 




common in non-pregnant women, this suggests there is a negative effect of undiagnosed 
hypercortisolism long before the diagnosis of CS. 
 
R.7.2. Evaluation of hypercortisolism during pregnancy is difficult; we suggest to consider 
testing only for high clinical suspicion of new diagnosis of Cushing’s disease. 
 
Rationale 
Making a new diagnosis of CS during pregnancy can be challenging because some of the 
clinical features overlap those occurring in normal pregnancy including hyperglycaemia, 
central weight gain, hypertension, fatigue, skin pigmentation, facial plethora and the 
development of striae. Clinical features which are not typical of normal pregnancy include 
striae on sites other than the abdomen and striae that are wider and more purple than 
usual for pregnancy, easy bruising, skin thinning, spontaneous fractures and proximal 
myopathy. However, biochemical confirmation is needed and this can be challenging. The 
HPA axis is activated during normal pregnancy producing increased levels of CRH (much of it 
originating from the placenta), ACTH and serum total and free cortisol (211). There is also 
increased hepatic production of cortisol binding globulin related to high levels of oestrogen, 
which further increases measured serum cortisol (211). Urine free cortisol (UFC) excretion 
increases up to 3-fold during pregnancy and overlaps with CS levels (269). Therefore, UFC 
values above this threshold are needed to be confident of the diagnosis. Suppression of 
cortisol by dexamethasone is blunted in pregnancy, so the 1mg overnight dexamethasone 
suppression test is not advised due to the risk of false positive results (269); up to 60% of 
normal pregnant women may fail to suppress below 50 nmol/L (1.8 µg/dL) (211). Because 
cortisol circadian rhythm is maintained in normal pregnancy (although at a higher level of 
cortisol), late night salivary cortisol or midnight serum cortisol levels have been suggested as 
possible diagnostic tests. Late night salivary cortisol levels also increase during pregnancy, 
but it has been reported that it may prove to be a valuable tool to diagnose CS in pregnancy 
with sensitivities of >80% and specificities of >93% using an ELISA-Cortisol EIA kit 
[salimetrics] and the following cut-offs: 0.255 µg/dL (7.0 nmol/L) for the 1st trimester, 0.260 
µg/dL (7.2 nmol/L) for the 2nd trimester, and 0.285 µg /dL (7.9 nmol/L) for the 3rd trimester 
(270). If confirmed with other assays, this may become the diagnostic test of choice when 




When the diagnosis of CS has been established, biochemical testing to determine the 
location is also challenging; insufficient data are available for high dose dexamethasone and 
CRH testing to make a recommendation (271). If a pituitary source is suspected based on 
high normal to elevated ACTH, pituitary MRI can be performed without gadolinium, 
although many corticotroph adenomas are small and may be missed. MRI with gadolinium 
could be performed during pregnancy given that no obvious adverse events have been 
reported, but the balance between the benefit and the potential risk should be carefully 
discussed. Bilateral inferior petrosal sinus sampling is not advised during pregnancy due to 
the radiation involved and the increased potential for venous thrombosis (272). When 
adrenal CS is suspected based on suppressed or low normal ACTH, ultrasound imaging of the 
adrenals may be performed but abdominal MRI without contrast seems best to characterise 
the adrenal mass.  
 
R.7.3. We recommend that in women with Cushing’s disease, medically treated and 
considering pregnancy, pros and cons of different therapeutic options to reduce cortisol 
concentrations should be carefully considered (). 
 
Rationale 
Treatment during pregnancy has been reported in less than 100 cases of endogenous CS of 
any origin, either surgery (24%), medical treatment (11%) or both (4.7%) (26). Only ten cases 
of Cushing’s disease with medical treatment during pregnancy were found in the literature 
(see section 4.3). Drugs most often reported were cabergoline, ketoconazole and 
metyrapone. However, none is approved for use in pregnancy. Adverse event rates were 
high for both mother (60%, 95%CI 26-88%) and infant (58%, 95%CI 28-85%) although no 
congenital malformations were reported. There are insufficient data about pasireotide and 
osilodrostat use in pregnancy; due to their side effects they should be avoided.  
The limited number of cases described precludes any definite conclusion as to the best 
management for CS during pregnancy; it depends on the cause, the stage of pregnancy and 
the severity of hypercortisolism. However, untreated CS is associated with more maternal 
and foetal morbidity. While medical or surgical treatment decreased the risk of perinatal 
mortality and maternal morbidity, it did not protect from prematurity or intrauterine 




If treatment is considered necessary, surgery in the second trimester has been 
recommended as a first choice treatment but evidence is limited (see 4.5). No specific 
congenital malformations appear to be more frequent in babies delivered from CS patients 
(26).  
 
R.7.4. We recommend that pregnant women with active or medically treated Cushing’s 
disease should be managed by a multidisciplinary team expert in high risk pregnancies.  
 
Rationale 
The multidisciplinary team should include obstetricians, pituitary specialists, neonatologists, 
and specialised endocrine surgeons. Mild cases of CS, especially those discovered late in 
pregnancy, may be treated conservatively by controlling co-morbidities. In women who 
become pregnant while on anti-cortisolic treatment (exception cabergoline), there should 
be discussion about the fact that little is known about possible teratogenic effects as well as 
maternal risk and pregnancy termination.  
In women who develop severe CD while pregnant, the first option to consider is surgery 
(pituitary adenomectomy or laparoscopic adrenalectomy) (273). In a systematic review of 
pregnancies in women diagnosed with CS, 61 underwent surgery at a gestational age of 21 
(range 17–26) weeks. Among these, 11 were transsphenoidal pituitary surgeries, 44 
unilateral adrenalectomies and 6 bilateral adrenalectomies. Seventy-seven percent attained 
remission, 12% were still active and in 10% information was not available. Foetal loss (6.7% 
vs. 28.6%), preterm birth (56.1% vs. 80%), and low birth weight (70.6% vs. 100%) were lower 
if remission was attained after surgery compared to those not in remission (26).  
Medical therapy can be contemplated when surgery is contraindicated, or initially after 
diagnosis for symptomatic control. Metyrapone has been most commonly used; as it may 
worsen hypertension and/or decrease potassium, blood pressure and potassium should be 
regularly monitored. Ketoconazole is another option for treatment, although fewer 
outcome data are available. Cabergoline has only been reported in 3 cases of CD with good 
maternal-foetal outcome, but breast feeding would not be possible. No reports of 
pasireotide or osilodrostat use during pregnancy in CS are available. Mifepristone, a 
glucocorticoid receptor blocker available in some countries, is contraindicated as it is also a 




The possibility of premature delivery should be anticipated in CD, and consideration given to 
induced early delivery if indicated. When control is not possible, with life-threatening risks 
for the mother and the foetus, pregnancy termination for medical reasons should be 
discussed.  
 
R.7.5. We suggest to consider treating pregnant women with active Cushing’s disease with 
prophylactic anticoagulation (low molecular weight heparin). 
 
Rationale 
CS increases the risk of thrombotic events up to 10-fold, which has been attributed to an 
increase in plasma clotting factors and impaired fibrinolysis (274-277). A recent cohort study 
of 208 patients with CS (89.4% of pituitary origin) showed an overall thrombotic rate of 18% 
(276). Anti-thrombotic prophylaxis has been shown to reduce morbidity and mortality in 
Cushing’s syndrome (275, 277). Separate from this, the risk of thrombosis is also increased 
in pregnancy. Therefore, risk might be even higher in pregnant women with CS. However, 
there are currently no data addressing the question of whether thromboprophylaxis would 
be beneficial and safe in pregnant women with CS. Given the clearly increased thrombosis 
risk, the panel concluded it is reasonable to consider prophylactic treatment with low 
molecular weight heparin.  
 
R.7.6. We recommend to re-assess disease activity after pregnancy.  
 
Rationale 
A reassessment of cortisol excess should be conducted after delivery in women with 
Cushing’s disease. In a woman without CS, the pregnancy-related HPA axis activation 
subsides within days after delivery and is typically back to non-pregnant levels within a few 
weeks (272, 278). Restoration of normal dexamethasone suppressibility of cortisol, 
however, may take over a month after delivery (211) and CBG elevations may be seen up to 
3 months post-partum (278). Therefore, re-assessment of disease state after delivery in a 





R.7.7. We recommend that breastfeeding be considered  
 
Rationale 
Breastfeeding is not contraindicated if the mother’s general condition allows it, and she is 
not taking steroid synthesis inhibiting drugs, pasireotide or cabergoline. 
 
 
Table 4 should be inserted here: Legend: Core recommendations 
 
6. Suggestions for future research 
 
Many questions still remain about the optimal management of pituitary tumours in 
pregnant women. We suggest that future research include the following questions: 
 
• Is transsphenoidal surgery for pituitary adenomas safe during pregnancy? 
• If surgery is needed for pregnant women with pituitary tumours, is there an optimal 
timing or can it be done during any trimester? 
• Are pasireotide and pegvisomant safe and effective in pregnant women with 
acromegaly? 
• Can the utility of trimester-based cutoffs for late-night salivary cortisol in pregnancy 
be confirmed? 
• Are there any novel methods that would establish the diagnosis of Cushing’s disease 
in pregnancy, given the activation of the hypothalamic-pituitary-adrenal axis in 
normal pregnancy? 
• Does therapy with low molecular weight heparin (LMWH) reduce the risk of 
thromboembolic events in pregnant women with Cushing’s disease? 
• Is LMWH safe for pregnant women and the foetus when used in Cushing’s disease? 
• What are the benefits and risks of medical treatment in pregnant women with 
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Figure 1: Flow diagram of study inclusion. 
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Table 1: Overview of the key clinical questions and outcome parameters. 
 
Clinical question Search criteria and key outcome parameters Number of papers 
included 
Question I: What is the safety profile and 
teratogenicity of medical treatment during 
pregnancy in patients with prolactinoma? 
 
Sub-question Ia: What is the safety profile 
and teratogenicity of medical treatment 
during pregnancy in patients with 
hyperprolactinaemia? 
 
Sub-question Ib: What is the safety profile 
and teratogenicity of bromocriptine and 
cabergoline during pregnancy in patients 
with prolactinoma and 
hyperprolactinaemia? 
 
Sub-question Ic: Is there a difference 
between patients who used medication only 
until confirmation of pregnancy and patients 
Population: Patients with prolactinoma or hyperprolactinaemia and pregnancy 
Medication during pregnancy: bromocriptine, cabergoline, (dihydro)ergocryptine, 
lergotrile, metergoline, and/or quinagolide  
Outcomes of the mother (prolactinoma): diagnosis of prolactinoma during pregnancy, 
stop and restart of medical treatment after pregnancy confirmation, spontaneous 
abortion or miscarriage, clinical progress/tumour symptoms, headache, gestational 
diabetes, gestational hypertension, pre-eclampsia 
Outcomes of the mother (hyperprolactinaemia): spontaneous abortion or miscarriage, 
termination of pregnancy due to malformation 
Outcomes of the infant: malformations, low birth weight, pre-term, small for 











who used medication during a larger part of 
pregnancy? 
Question II: What is the safety profile and 
teratogenicity of medical treatment during 
pregnancy in patients with acromegaly? 
 
Sub-question IIa: Is there a difference 
between patients who used medication only 
until confirmation of pregnancy and patients 
who used medication during a larger part of 
pregnancy? 
Population: Patients with acromegaly and pregnancy 
Medication during pregnancy: bromocriptine, cabergoline, dopamine agonist 
(unspecified), octreotide, lanreotide, pasireotide, somatostatin analogue (unspecified), 
and/or pegvisomant 
Outcomes of the mother: diagnosis of acromegaly during pregnancy, stop of medical 
treatment after pregnancy confirmation, spontaneous abortion or miscarriage, clinical 
progress/tumour symptoms, headache, gestational diabetes, gestational hypertension, 
pre-eclampsia 
Outcomes of the infant: malformations, low birth weight, pre-term, small for 
gestational age, macrosomia, neonatal death 
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Question III: What is the safety profile and 
teratogenicity of medical treatment during 
pregnancy in patients with Cushing’s 
disease? 
Population: Patients with Cushing’s disease and pregnancy 
Medication during pregnancy: metyrapone, ketoconazole, mitotane, and/or 
cabergoline 
Outcomes of the mother: gestational diabetes, gestational hypertension, pre-
eclampsia, hypothyroidism, no milk for breastfeeding 
Outcomes of the infant: malformations, low birth weight, pre-term, small for 
gestational age, neonatal death 
10 
Question IV: What is the incidence of 
tumour growth during pregnancy in patients 
with a non-functioning or functioning 
Population: Patients with a non-functioning or functioning (prolactinoma, acromegaly, 
or Cushing’s disease) adenoma and pregnancy (minimum 10 patients per study) 







(Cushing’s disease, acromegaly, or 
prolactinoma) adenoma? 




pituitary adenoma: 1 
Question V: Is pituitary surgery safe for 
pituitary adenomas during pregnancy? 
 
Sub-question Vb: What is the effectiveness 
of pituitary surgery for pituitary adenomas 
during pregnancy? 
Population: Patients with a pituitary adenoma and pregnancy 
Treatment: transsphenoidal adenomectomy 
Outcomes of the mother: diabetes insipidus, SIADH, cerebrospinal fluid leakage, 
gestational diabetes, gestational hypertension, pre-eclampsia 
Outcomes of the infant: low birth weight, pre-term, small for gestational age, neonatal 







Table 2: Work-up when pregnancy is considered. 
 
Medical history with special attention to pituitary condition and its associated 
comorbidities  
Physical examination including body mass index calculation and blood pressure 
Routine laboratory values including electrolytes, glucose, liver and kidney function tests, 
lipids, urine dipstick 
Representative evaluation of pituitary hormone status (overproduction and deficiency), 
and reproductive status  
Consider: Early morning cortisol, ACTH, fT4, TSH, E2, LH, FSH, progesterone (on day 21 of 
menstrual cycle), SHBG, PRL, IGF-I, DHEA-S, testosterone, AMH (on day 3 of menstrual 
cycle)* 
Representative tumour volume status, with dedicated pituitary MRI depending on initial 
size (macroadenoma) and time since last evaluation 
Representative neuro-ophthalmological evaluation if clinically indicated (depending on 
size and location of the lesion, especially if it is in contact with the optic chiasm) 
 






Table 3: Safety and teratogenicity outcomes after treatment of hyperprolactinaemia during pregnancy using cabergoline. 
 


















Auriemma 2013 143; 126 13 2 0 0 0 0 0 
Colao 2008 329; 258 30 17 0 45 17 6 0 
Domingue 2014 36; 39 0 0 0 4 0 0 0 
Karaca 2018 45; 39 6 3 2 2 2 Not reported 0 
Lebbe 2010 100; 88 10 9 5 8 3 3 0 
Ono 2010 85; 83 2 9 Not 
reported 
1 0 0 0 
O’Sullivan 2019 41; 36 4 0 2 6 1 0 0 
Rastogi 2016 48; 39 6 3 3 0 0 3 0 
Ricci 2002 61; 49 6 6 Not 
reported 
4 2 1 0 
Sant’ Anna 2019 233; 194 27 9 3 6 7 0 1 




Webster 1993 26; 22 0 0 0 0 0 1 0 
Total cohort 
studies 
1250; 1063 111 (8.9%) 59 (5.6%) 16 (1.7%) 84 (7.9%) 35 (3.3%) 14 (1.2%) 1 (0.1%) 
Case reports / case series 
Almistehi 2018 
 
1; 1 0 1 1 0 0 0 0 
Bajwa 2011 1; 1 0 0 0 1 0 0 0 
Banerjee 2009 4; 3 1 0 0 0 0 0 0 
Cannavò 1999 
 
6; 5 1 0 0 0 0 0 0 
Couture 2012 1; 1 0 0 0 0 0 0 0 
Galvão 2017 4; 4 0 0 0 Not 
reported 
0 0 0 
Jones 1994 2; 1 1 1 1 0 0 0 0 
Jones 1997 1; 1 0 0 0 0 0 0 0 
Mitsiakos 2019 1; 1 0 1 1 1 1 0 0 
Shahzad 2012 1; 1 0 0 0 0 0 0 0 





% (95% CI) 


































Prolactinoma Acromegaly Cushing’s disease 
Pre-conception In women with an NFA near 
the optic chiasm who are 
seeking pregnancy, surgery 
may be considered to reduce 
the risk of chiasmal 
compression and to enhance 
fertility 
Aim for normalisation of even 
mild hyperprolactinaemia 
with cabergoline at the lowest 
possible dose to optimise 
chances to conceive  
Consider surgery in active 
acromegaly before 
pregnancy 
Advise against pregnancy 
during active Cushing’s 
disease 
Pregnancy Nonfunctioning 
microadenomas bear a low 
risk for growth during 
pregnancy, there is no need 
for routine monitoring 
No indication for prolactin 
testing 
Medical treatment should be 
stopped in most cases upon 
confirmation of pregnancy 
Close surveillance is needed in 
women with a 
macroprolactinoma 
No indication for GH 
and/or IGF-1  testing 
Medical treatment should 
be stopped in most cases 
upon confirmation of 
pregnancy 
Diagnosis of Cushing’s disease 
and assessment of disease 
activity is challenging due to 
placental CRH production and 
activation of the 
hypothalamic-pituitary-
adrenal axis, circadian rhythm 
however is preserved   
Post-pregnancy We recommend awaiting re-
assessment of pituitary 
imaging and function until  
3-6 months after delivery 
A significant percentage of 
prolactinomas are 
biochemically in remission 
after pregnancy and lactation  
Rebound of disease 
activity shortly after 
delivery is frequent 
Re-assessment of disease 
activity should be performed 
2-3 months post partum 
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